The company’s new product, Arbidol Hydrochloride, was officially approved for market launch on March 19, 2020.
Release date:
2020-04-01
The antiviral product arbidol hydrochloride has played a significant role in the current fight against the epidemic, earning widespread recognition from medical institutions. It is poised to become a mainstay treatment for influenza A, influenza B, and coronaviruses, serving as a new growth driver for the company.
The antiviral product arbidol hydrochloride has played a significant role in the current fight against the epidemic, earning widespread recognition from medical institutions. It is poised to become a mainstay treatment for influenza A, influenza B, and coronaviruses, serving as a new growth driver for the company.
Related News
Leave a Message Online
Consultation Service Hotline
Address: No. 509, East Lin Road, Bio-Industrial Park, High-tech Zone, Yichang City, Hubei Province, China
International Marketing Department
Contact: Vivian Guo
Email: Vivian.guo@tianrenpharm.com
Phone: 86-15997560212
WhatsApp: +86-15997560212
Website Development:China Enterprise Dynamics Yichang right of privacy
This website supports both IPv4 and IPv6 bidirectional access.